cyrilzakka/clinical-trials huggingface dataset:
Regulation of Different IT on Vascular Function of Overweight Female University Students

This study investigates the effects of different interval training methods, specifically high-intensity interval training (HIIT) and sprint interval training (SIT), on vascular function in overweight female university students. A randomized controlled trial was conducted over an 8-week period.

This study aimed to evaluate how different types of interval training (HIIT and SIT) influence vascular function in overweight female university students. Participants were initially enrolled and randomly assigned to HIIT, SIT, or control groups. The participants in HIIT and SIT groups underwent an 8-week supervised exercise program 3 times per week on a treadmill. Both pre- and post-intervention measurements were taken, including vascular function, morphological indicators, and blood markers. This study highlights the potential of interval training as a time-efficient and effective intervention for improving cardiovascular health and body composition in this population.

Eligibility Criteria:
Inclusion Criteria:

* Participants aged between 18 and 25 years, female.
* Participants' BMI more than 24 kg·m-2.
* Participants without regular exercise habits.

Exclusion Criteria:

* Participants underwent other interventions (e.g., nutrition, psychology, exercise, health education, et al).
* Participants had a history of systematic and professional exercise habit.
* Participants presenced of disease or condition restricting participation, such as injuries, respiratory disease or cardiovascular diseases.
Compare the Healing Process of Idiopathic Macular Hole With Different Surgical Techniques

To compare anatomic and functional results, and to evaluate postoperatively the healing process in 2 different techniques for the closure of the macular holes (MH)

Patients with macular holes classified in stages 3 and 4 will be randomized into 2 groups. . In Group A, patients will undergo peeling with complete removal of the internal limiting membrane (ILM) and in the group B, the inverted ILM peeling technique will be performed. The 20% sulfur hexafluoride (SF6) gas will be used as a tamponade agent in all surgeries, and patients will be instructed to avoid the prone position for 5 days.

OCT images will be performed in the first 5 postoperative days and months 1, 3 and 6.

The primary outcome is anatomic closure of the MH closure in the month 6. The second outcomes are: mean best corrected visual acuity (BCVA) at month 6, mean change in the BCVA at month 6; integrity of the perifoveal external limiting membrane and ellipsoid zone on Optical Coherence Tomography (OCT); MH closure rate over time in days; functional improvement of microperimetry Statistical analysis will be performed with Student t-test and the p-value of ≤ 0.05 is considered significant.

Eligibility Criteria:
Inclusion Criteria:

\> Stage 3 and 4 macular holes with visual acuity between 20/30 and 20/800 according to the ETDRS chart.

Exclusion Criteria:

* Macular holes secondary to ocular trauma, myopia or retinal detachment
* Any previous treatment for the macular hole
* Evidence on examination of any diabetic retinopathy
* History or presence of wet or dry age macular degeneration (AMD)
* Presence of epiretinal membrane or prior uveitis
* Any ocular surgery within 3 months before baseline
* Intra or periocular infection
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease

The purpose of this study is to investigate whether mutations in genes coding for Na/Pi-cotransporters are associated with aortic valve calcification. A patient population with premature aortic valve calcification treated with aortic valve replacement will be screened for mutations in these specific genes. Furthermore, aortic valve tissue received from the operations, will be examined for the presence of Na/Pi-cotransporters, and for molecular characterization of the transporters.


Eligibility Criteria:
Inclusion Criteria:

* Patients with aortic valve calcification that will be treated with an aortic valve replacement.
* Age ≤ 65 years.
* Signed and dated informed consent.

Exclusion Criteria:

* Inability to provide informed consent
* Earlier radiation therapy of the thorax
* Severe renal disease (patients in treatment with dialysis)
Comparative Evaluation of Three Airway Maneuvers in the Unconscious Apneic Person

One-handed E-C clamp mask holding technique, two-handed mask ventilation with jaw thrust, and two-handed mask ventilation with triple airway maneuver are three common airway management maneuvers. Sniffing position may improve ventilation between these three maneuvers. The investigators hypothesize that ventilation efficiency may be different between these three maneuvers whether the patient is in sniffing position or neutral position. The investigators would like to quantify this effect by measuring the expired tidal volume, airway pressure, EtCO2 slope and hemodynamic change between these three maneuvers during anesthesia induction.

Mask ventilation is considered a important skill for airway management during general anesthesia induction and for apneic unconscious patients. One-handed E-C clamp mask holding technique, two-handed mask ventilation with jaw thrust, and two-handed mask ventilation with triple airway maneuver are three common airway management maneuvers. However, the efficiency of ventilation between these three maneuvers has to be clarified. Besides, whether sniffing position or neutral position may improve ventilation between these three maneuvers is to be determined. The investigators will collect airway parameters of the patients receiving general anesthesia and measure the expired tidal volume, airway pressure, EtCO2 slope and hemodynamic change between these three maneuvers during anesthesia induction.

Eligibility Criteria:
Inclusion Criteria:

* adult patients(ASA I-III) scheduled for elective surgery requiring general anesthesia with endotracheal intubation.

Exclusion Criteria:

* pneumothorax
* SpO2\<96%(without additional oxygen supply)
* vocal cord palsy
* congenital airway abnormality
* facial trauma or deformity
* acute upper airway disease
* inadequate fasting time
* neck or potential cervical spine disease
* temporal-mandible joint abnormality
* head and neck tumor
* status post radiotherapy
* pregnancy
* long term sedative or opioid drug use
* patient refuse
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)

The study is to provide reliable estimates of the effect of study treatment on hospital length of stay through to 28 days after randomisation.

The protocol describes an overarching trial design to provide reliable evidence on the efficacy of candidate therapies for children hospitalised with PIMS-TS. It is an adaptive pragmatic platform trial with an open-label randomisation.

New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.

In May 2020 a new COVID-associated inflammatory syndrome in children was identified, Paediatric Inflammatory Multisystem Syndrome - Temporally associated with SARS-CoV-2 (PIMS-TS). A rapid international consensus process identified the need to evaluate corticosteroids and intravenous immunoglobulin (IVIg) as initial therapies in PIMS-TS, and confirmed tocilizumab and anakinra as biological anti-inflammatory agents to be evaluated as a second line therapy.

This Swissped-Recovery trial is a sister trial to the RECOVERY international trial with the implementation of the study at Swiss study sites.

The protocol describes an overarching trial design to provide reliable evidence on the efficacy of candidate therapies for children hospitalised with PIMS-TS. It is an adaptive pragmatic platform trial with an open-label randomisation.

New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.

Additional substudies can be added to provide more detailed information on side effects or sub-categorisation of patient types.

Eligibility Criteria:
Inclusion Criteria:

* Hospitalised children (aged \<18 years old)
* SARS-CoV-2 infection associated disease (clinically suspected or laboratory confirmed) with evidence of single or multi-organ dysfunction (called Pediatric Multisystem Inflammatory Syndrome temporally associated with COVID-19 \[PIMS-TS\]).
* No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial

Exclusion Criteria:

* Neonates/infants with a corrected gestational age of \<= 44 weeks
* If the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms or that the patient should definitely be receiving one of the active drug treatment arms, then that arm will not be available for randomisation for that patient.
Effect of Remimazolam and Sevoflurane Anesthesia on Recovery in Pediatric Patients

The most commonly used anesthetic for general anesthesia in pediatric patients is sevoflurane, an inhalation anesthetic. However, the incidence of emergence agitation after sevoflurane anesthesia in pediatric patients is high, with reports of up to 67%. Remimazolam (Byfavo Inj., Hana Pharm Col, Ltd., Seoul, Korea) has a short context-sensitive half-life of 7.5 minutes, and the time it takes from the end of anesthesia until the patient wakes up is predictable. According to a study by Yang X et al., administering a small amount of remimazolam (0.2 mg/kg) intravenously at the end of general anesthesia using sevoflurane reduced the incidence of emergence agitation. However, very few studies have evaluated the use of remimazolam in general anesthesia in pediatric patients.

* The most commonly used anesthetic for general anesthesia in pediatric patients is sevoflurane, an inhalation anesthetic. It has the advantage of being able to induce anesthesia without securing an intravenous route and causing less irritation to the airway. However, the incidence of emergence agitation after sevoflurane anesthesia in pediatric patients is high, with reports of up to 67%. Emergence agitation can cause physical damage to the patient, workload in the recovery room, and dissatisfaction of the caregiver.
* Remimazolam (Byfavo Inj., Hana Pharm Col, Ltd., Seoul, Korea) is a benzodiazepine drug used for inducing and maintaining general anesthesia and for sedation during procedures. When remimazolam is used as a general anesthetic, it has the advantage of being metabolized quickly by enzymes in the liver compared to propofol, has a short context-sensitive half-life of 7.5 minutes, and can be reversed with flumazenil. Therefore, during general anesthesia using remimazolam, the time it takes from the end of anesthesia until the patient wakes up is predictable. According to a study by Yang X et al., administering a small amount of remimazolam (0.2 mg/kg) intravenously at the end of general anesthesia using sevoflurane reduced the incidence of emergence agitation.
* However, very few studies have evaluated the use of remimazolam in general anesthesia in pediatric patients and its effect on endotracheal extubation time after anesthesia in operating room, emergence agitation, pain, and discharge time in the postanesthesia care unit (PACU).

Eligibility Criteria:
Inclusion Criteria:

* Patients aged between 3 and 18 years old who underwent ophthalmic surgery under general anesthesia
* When anesthesia was induced and maintained with remimazolam, or anesthesia was induced with propofol and maintained with sevoflurane.

Exclusion Criteria:

- none
Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence

Randomized controlled trial (RCT) to evaluate the effectiveness of applying Purell® (62% ethyl alcohol in emollient gel) to the penis of male partners of women diagnosed with BV for preventing BV recurrence after treatment.


Eligibility Criteria:
Inclusion criteria:

* Vaginal symptoms
* Nugent score \> 6 for vaginal fluid gram stain
* Woman and her male partner both interested in study participation
* Woman able to return for follow-up visits
* Woman able to provide detailed contact information for tracing

Exclusion Criteria:

* Either male or female partner not recruited within 24 hours of the other
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT

Comparing the effect of two different duration of same drug albendazole in patients with Neurocysticercosis less than or equal to 5 lesions on CT head at the end of 6 months.

The trial will be comparing the effectiveness of short and long duration of albendazole ie 7 and 28 days therapy in patients with parenchymal neurocysticercosis in terms of complete resolution or calcification of cyst on CT head at the end of 6 months after starting albendazole

Eligibility Criteria:
Inclusion Criteria:

* Age 2-18 years.
* Number of parenchymal lesions: upto 5\*
* Stages of cysticerci at which albendazole treatment is effective
* Vesicular stage
* Colloid vesicular stage
* Granular nodular stage

Exclusion Criteria:

* Cysticercotic encephalitis
* Calcified cyst
* Hydrocephalus
* Intraventricular cyst
* Subarachnoid cyst
* Ophthalmic Cysticercosis
* No of cysts \>5
* Known allergy to benzimidazole class of compound which includes anaphylaxis, hypotension, severe skin reactions .
* Features of raised ICT (papilloedema, hyperventilation, hypertension, tonic posturing, B/L 6th nerve palsy, features of midline shift on CT/MRI)
* Critically sick (respiratory failure, cardiovascular instability)
* Already received albendazole or praziquantel or steroid therapy
A Study of LY3050258 in Healthy Participants

This is a multiple dose study of LY3050258 in healthy men and postmenopausal women. This study will evaluate the safety and how well the body tolerates LY3050258. It will last approximately 14 weeks with a 2 week follow-up appointment after the last treatment with study drug.


Eligibility Criteria:
Inclusion Criteria:

* Healthy males or healthy postmenopausal females, including Japanese participants
* Body mass index (BMI) of 18 and 35 kilograms per square meter (kg/m\^2), inclusive

Exclusion Criteria:

* Abnormal siting blood pressure as determined by the investigator
* Abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, places the participant at an unacceptable risk for study participation
* Aspartate aminotransferase (AST) or alkaline phosphatase (ALT) greater than 2 times the upper limit of normal (ULN)
* Skin condition that in the opinion of the investigator makes the participant unsuitable for study participation
* Current use of statins within the last 3 months prior to dosing
* Current use or previous use of anabolic steroids in the preceding 6 months prior to dosing
* Use of dehydroepiandrosterone, other potential over-the-counter steroidal supplements, or other nutritional products intended to have weight-reduction and/or performance-enhancing effects within 21 days prior to dosing
Genomic Medicine for Ill Neonates and Infants (The GEMINI Study)

The Genomic Medicine for Ill Neonates and Infants (The GEMINI Study) is a research study aimed at comparing the clinical and economic utility of performing rapid whole genomic sequencing versus a targeted genomic sequencing panel on neonates and infants suspected of having a genetic disorder. This study is funded by the National Institutes of Health.

This multicenter, prospective clinical trial will enroll 400 subjects at the Floating Hospital for Children at Tufts Medical Center (Boston, MA), Cincinnati Children's Hospital Medical Center (Cincinnati, OH), Mount Sinai Kravis Children's Hospital (New York, NY), North Carolina Children's Hospital (Chapel Hill, NC), Children's Hospital of Pittsburgh (Pittsburgh, PA), and Rady Children's Hospital (San Diego, CA).

This multicenter, prospective clinical trial will examine the diagnostic yield and clinical utility of NewbornDx, a targeted genomic sequencing panel for use in the neonate, and rapid whole genomic sequencing (rWGS) testing in high-risk infants with signs/symptoms consistent with a possible genetic disorder. Infants will undergo NewbornDx and rWGS (proband) testing. The biological parent(s), when available, will undergo NewbornDx testing at the same time as the infant. For rWGS,the infant will undergo testing first. If a specific diagnosis that is consistent with the phenotype is not made with rWGS proband analysis alone, the parent(s) will undergo rWGS. The study will also evaluate the cost effectiveness of each test as well as standard of care (SOC) testing. A retrospective chart review of infants with suspected genetic disorders will be done to understand 1-year cost and health outcomes that would have been incurred in the absence of the advanced testing. The resulting data from the trial will be used in the economic evaluation comparing NewbornDx, rWGS, and SOC over a 1-year period and used as basis to simulate the lifetime cost-effectiveness of these testing strategies. A web-based clinical reference database to provide references, clinical management guidelines, opportunities for clinical trial participation, and support groups for each condition will be developed with separate interfaces for the parent/guardian(s) and medical provider. The clinical reference database will be qualitatively assessed by a survey of medical providers.

Eligibility Criteria:
Inclusion Criteria:

* Documented informed consent from the parent/guardian
* Signs/symptoms consistent with a possible genetic disorder
* Admitted to a hospital participating in this study at the time of enrollment
* Less than one year corrected gestational age

Exclusion Criteria:

* A known genetic diagnosis (e.g. prenatal testing)
* Major congenital anomaly associated with a chromosomal anomaly detected on prenatal testing
* Presence of documented congenital infection
* Infants considered non-viable due to prematurity (\< 23 0/7 weeks GA)
The Ability of Anesthesiologists Identifying Internal Jugular Vein Bilaterally by Anatomic Landmarks

The study is designed to determine anaesthetists ability to locate the right internal jugular vein(IJV) and left IJV using a landmark technique. Initially, a questionnaire was completed detecting previous user experience. An ultrasound probe, using the midpoint as an 'imaginary needle', was placed on the neck of a healthy volunteer and the image recorded. Both anaesthetist and volunteer were blinded to the screen until the image was stored. Anaesthetists were grouped into senior or junior by the total number of IJV canulation experience. The success rate is going to be measured as pass or fail.

Anesthesiologists are usually qualified in internal jugular vein canulation by using anatomic landmark technique. The anatomy of right IJV and left IJV may differ each other. The hypothesis is that the anatomical difference between right and left IJV may give rise to false puncture of especially left IJV by using anatomical landmark technique.Although USG is available, most of the experienced anesthesiologist does not prefer to use USG for IJV canulation due to different reasons.In addition to this anesthesiologists are generally preferring right IJV canulation, thus they are inexperienced in left IJV canulation. So especially during left IJV canulation,not by anatomical landmark technique but by USG will be recommended for anesthesiologists.

Eligibility Criteria:
Inclusion Criteria:

* The voluntary anesthesiologists who are studying in diskapi training and research hospital

Exclusion Criteria:

* The anesthesiologists who are not willing to participate, the anesthesiologists whom refused to fulfill the questionnaire form.
CASUS vs. APACHE II in Predicting Mortality After Coronary Artery Bypass Grafting

The study seeks to determine the value of CASUS in predicting mortality as compared with APACHE II scoring system among patients undergoing coronary artery bypass grafting.

Patients undergoing coronary artery bypass grafting will prospectively studied after the admission to the cardiac intensive care unit. Data on the preoperative condition, intraoperative parameters, and postoperative course will collected. CASUS and APACHE II scores will calculated on the first postoperative day. Clinical outcomes are defined as 7-day mortality, 30-day mortality and morbidity. Morbidity includes variables such as length of stay in the cardiac surgical intensive care unit and in the hospital.

Eligibility Criteria:
Inclusion Criteria:

* Undergoing coronary artery bypass grafting
* Over 18 years of age
* Staying at least 24 hours in the cardiac intensive care unit

Exclusion Criteria:

* Emergency surgery
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression

The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients, 18 to 60 years of ages, inpatients or outpatients. Inpatients are qualified only if they are hospitalized for current episode of bipolar depression and should be able to leave hospital when clinical criteria are no longer met for acute inpatient hospitalization
* Patients must fulfill the criteria for bipolar I depression (bipolar I disorder, current episode major depressive) as defined in DSM-IV-TR based on clinical examination and psychiatric assessment
* Patients must have experienced, in the opinion of the investigator, at least one previous manic or mixed episode as defined in DSM-IV-TR, of sufficient severity to require treatment with a mood stabilizer or an antipsychotic as reported by the patient or the caregiver
* Each patient must have a level of understanding sufficient to perform all tests and examinations required by the protocol
* Female patients must test negative for pregnancy and must be using a medically accepted means of contraception

Exclusion Criteria:

* Current diagnosis of any of the following according to DSM-IV-TR criteria: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Delirium of any type, Dementia of any type, Amnestic Disorder, any Substance-Induced Disorder, or any Psychotic Disorder due to a General Medical Condition, unless there is substantive reason to believe patient was previously misdiagnosed.
* Treatment with clozapine within 3 months (90 days) prior to visit 1
* Treatment with electroconvulsive therapy (ECT) within 3 months (90 days) prior to visit 2
* Patients with seizure disorders are excluded (except patients with a previous history of seizures due to alcohol withdrawal, which have resolved).
* Participation in a clinical trial of another drug including olanzapine, fluoxetine or lamotrigine within 30 days prior to study entry (visit 1)